{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.7","value":"58.1"},{"groupId":"OG001","spread":"21.7","value":"58.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"367"},{"groupId":"OG001","value":"375"}],"units":"Participants"}],"title":"Cycle 1 Day 1 (Baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.4","value":"56.8"},{"groupId":"OG001","spread":"20.4","value":"59.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"334"},{"groupId":"OG001","value":"356"}],"units":"Participants"}],"title":"Cycle 3, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.7","value":"58.9"},{"groupId":"OG001","spread":"20.1","value":"62.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"284"},{"groupId":"OG001","value":"326"}],"units":"Participants"}],"title":"Cycle 6, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.7","value":"57.3"},{"groupId":"OG001","spread":"19.6","value":"62.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"212"},{"groupId":"OG001","value":"255"}],"units":"Participants"}],"title":"Cycle 12, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.8","value":"59.9"},{"groupId":"OG001","spread":"19.2","value":"64.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"226"}],"units":"Participants"}],"title":"Cycle 18, Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"367"},{"groupId":"OG001","value":"375"}],"units":"Participants"}],"description":"Health-related quality of life was assessed with the use of the European Organization for Research and Treatment of Cancer Quality of Life Core Module (QLQ-C30) questionnaire, a validated instrument in multiple myeloma patients. Scores range from 0 to 100, with higher scores indicating better health related quality of life.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received their randomized study treatment in 28-day cycles until disease progression or unacceptable toxicity. Lenalidomide 25 mg was administered orally on days 1 to 21 and dexamethasone 40 mg was administered orally or intravenously on days 1, 8, 15, and 22.","id":"OG000","title":"Lenalidomide and Dexamethasone (Rd)"},{"description":"Participants received their randomized study treatment in 28-day cycles until disease progression or unacceptable toxicity. Carfilzomib 20 mg/m² was administered intravenously (IV) on days 1 and 2 of cycle 1, then escalated to 27 mg/m² on Days 8, 9, 15, and 16 of cycle 1 and continuing on days 1, 2, 8, 9, 15, and 16 of cycle 2 through cycle 12 and then from cycle 13 through cycle 18, 27 mg/m² on days 1, 2, 15, and 16. Lenalidomide 25 mg was administered orally on days 1 to 21 of every cycle. Dexamethasone 40 mg was administered orally or IV on days 1, 8, 15, and 22 of every cycle.","id":"OG001","title":"Carfilzomib, Lenalidomide, and Dexamethasone (CRd)"}],"paramType":"MEAN","populationDescription":"ITT analysis set participants with a baseline value.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 (Baseline), Day 1 of Cycles 3, 6, 12, 18","title":"Quality of Life Core Module (QLQ-C30) Global Health Status/Quality of Life Scores","type":"SECONDARY","unitOfMeasure":"scores on a scale"}